James Quigley
Stock Analyst at Morgan Stanley
(0.91)
# 3,725
Out of 4,876 analysts
22
Total ratings
66.67%
Success rate
-15.36%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Upgrades: Overweight | $49 → $79 | $44.12 | +79.06% | 6 | Jun 3, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $47.85 | +35.84% | 1 | Mar 21, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | $119 → $121 | $120.01 | +0.82% | 1 | Sep 5, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $8.87 | +18.38% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $28.01 | +42.81% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $4.16 | +284.62% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Jun 3, 2025
Upgrades: Overweight
Price Target: $49 → $79
Current: $44.12
Upside: +79.06%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $47.85
Upside: +35.84%
Novartis AG
Sep 5, 2024
Downgrades: Neutral
Price Target: $119 → $121
Current: $120.01
Upside: +0.82%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.87
Upside: +18.38%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $28.01
Upside: +42.81%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $4.16
Upside: +284.62%